News archive for Brain tumour immunology and therapy group
This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.
- August 2024 (1)
- June 2024 (3)
- September 2023 (2)
- May 2023 (1)
- September 2021 (1)
- May 2021 (1)
- March 2021 (1)
- February 2021 (1)
- October 2020 (1)
- September 2019 (1)
- August 2019 (1)
- November 2018 (1)
- October 2018 (1)
- May 2018 (1)
- April 2018 (1)
- November 2017 (1)
- June 2014 (1)